Skip to main content

Table 3 Summary results of the all-grade and grade ≥ 3 adverse events (AEs) in combination therapies

From: Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

adverse events All-grade Grade ≥ 3
No. of Studies No. of Patients model Event rate with 95% CI Z value p value No. of Studies No. of Patients model Event rate with 95% CI Z value p value
Hematologic
 Anaemia 2 53 Random 0.687 (0.017–0.996) 0.319 0.750       
 Lymphopenia 2 119 Random 0.619 (0.007–0.997) 0.176 0.861 2 119 Random 0.568 (0.004–0.998) 0.092 0.927
 Thrombocytopenia 3 143 Random 0.248 (0.006–0.951) −0.534 0.593       
 Neutropenia 2 42 Random 0.812 (0.035–0.998) 0.600 0.549       
Gastrointestinal disorders
 Gastrointestinal disorder 2 53 Random 0.599 (0.001–0.999) 0.112 0.911       
 Nausea 3 127 Random 0.159 (0.046–0.425) −2.393 0.017       
 Vomiting 3 127 Random 0.093 (0.032–0.242) −3.945 0.000       
 Diarrhea 2 103 Fixed 0.148 (0.091–0.231) −6.240 0.000       
 Stomatitis 3 143 Random 0.185 (0.035–0.585) −1.592 0.111 2 119 Random 0.046 (0.004–0.393) −2.290 0.022
General disorders
 Fatigue 3 127 Random 0.278 (0.072–0.659) −1.159 0.246       
 Pyrexia 3 143 Random 0.234 (0.017–0.844) −0.810 0.418       
 Chills 2 37 Fixed 0.110 (0.042–0.260) − 3.930 0.000       
 Oedema peripheral 2 37 Fixed 0.056 (0.014–0.200) −3.863 0.000       
Injury, poisoning and procedural complications
 Infusion related reaction 2 37 Fixed 0.110 (0.042–0.260) −3.930 0.000       
Metabolism and nutrition disorders /investigations
 AST increased 2 119 Random 0.163 (0.036–0.501) −1.956 0.050 2 119 Fixed 0.059 (0.028–0.119 −7.103 0.000
 ALT increased 2 119 Random 0.197 (0.030–0.663) −1.325 0.185 2 119 Fixed 0.044 (0.019–0.102) −6.696 0.000
 Hyponatraemia 2 119 Random 0.060 (0.009–0.301) −2.825 0.005 2 119 Random 0.032 (0.005–0.170) −3.659 0.000
 Hyperuricaemia 2 37 Fixed 0.056 (0.014–0.200) −3.863 0.000       
 Hypomagnesaemia 2 37 Fixed 0.056 (0.014–0.200) −3.863 0.000       
 Hypophosphataemia 2 53 Fixed 0.116 (0.053–0.236) − 4.663 0.000       
 Weight decreased 2 37 Fixed 0.113 (0.043–0.265) − 3.878 0.000       
 Platelet count decreased 2 103 Fixed 0.050 (0.021–0.114) −6.436 0.000       
 Decreased appetite 3 143 Random 0.275 (0.031–0.817) −0.769 0.442       
 Dehydration 2 37 Fixed 0.204 (0.099–0.373) −3.166 0.002       
 Hypotension 2 114 Fixed 0.021 (0.005–0.082) −5.334 0.000       
Musculoskeletal and connective tissue disorders
 Arthralgia 2 37 Fixed 0.113 (0.043–0.265) −3.878 0.000       
 Musculoskeletal chest pain 2 37 Fixed 0.056 (0.014–0.200) −3.863 0.000       
 Myalgia 3 127 Fixed 0.041 (0.017–0.095) −6.889 0.000       
 Abdominal pain 2 37 Fixed 0.081 (0.026–0.223) − 4.029 0.000       
 Neck pain 2 37 Fixed 0.081 (0.026–0.223) −4.029 0.000       
 Back pain 2 37 Fixed 0.056 (0.014–0.200) −3.863 0.000       
 Chest pain 2 37 Fixed 0.056 (0.014–0.200) − 3.863 0.000       
Skin and subcutaneous tissue disorders
 Rash 2 114 Fixed 0.370 (0.286–0.462) −2.741 0.006       
 Rash maculo-papular 2 114 Fixed 0.182 (0.121–0.266) −6.046 0.000       
 Skin exfoliation 2 114 Fixed 0.035 (0.013–0.090) − 6.501 0.000       
 Dry skin 2 114 Fixed 0.070 (0.036–0.135) −7.033 0.000       
Infections and infestations
 Sepsis 2 37 Random 0.139 (0.017–0.607) −1.584 0.113       
 Pneumonia 2 53 Fixed 0.116 (0.053–0.236) −4.663 0.000       
 Pneumonitis 2 114 Fixed 0.021 (0.005–0.082) −5.334 0.000       
 Urinary tract infection 2 37 Fixed 0.056 (0.014–0.200) −3.863 0.000       
Nervous system and psychiatric disorders
 Dysgeusia 2 114 Fixed 0.044 (0.018–0.101) −6.738 0.000       
 Headache 2 37 Fixed 0.142 (0.060–0.300) −3.712 0.000       
 Insomnia 2 37 Fixed 0.110 (0.042–0.260) −3.930 0.000       
 Malaise 2 114 Fixed 0.048 (0.020–0.110) −6.509 0.000